CP-690550 Treatment Ameliorates Established Disease and Provides Long-Term Therapeutic Effects in an SKG Arthritis Model
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Although pathogenesis of human rheumatoid arthritis (RA) remains unclear, arthritogenic T cells and downstream signaling mediators have been shown to play critical roles. An increasing numbers of therapeutic options have been added for the effective control of RA. Nevertheless, there is still a category of patients that fails treatment and suffers from progressive disease. The recently developed immunosuppressant CP-690550, a small molecule JAK kinase inhibitor, has been implicated as an important candidate treatment modality for autoimmune arthritis. In this study, we evaluated the therapeutic effect of CP-690550 on established arthritis using an SKG arthritis model, a pathophysiologically relevant animal model for human RA. CP-690550 treatment revealed remarkable long-term suppressive effects on SKG arthritis when administered to the well-advanced disease (clinical score 3.5∼4.0). The treatment effect lasted at least 3 more weeks after cessation of drug infusion, and suppression of disease was correlated with the reduced pro-inflammatory cytokines, including IL-17, IFN-γ, and IL-6 and increased level of immunoregulatory IL-10.
Abstract
Although pathogenesis of human rheumatoid arthritis (RA) remains unclear, arthritogenic T cells and downstream signaling mediators have been shown to play critical roles. An increasing numbers of therapeutic options have been added for the effective control of RA. Nevertheless, there is still a category of patients that fails treatment and suffers from progressive disease. The recently developed immunosuppressant CP-690550, a small molecule JAK kinase inhibitor, has been implicated as an important candidate treatment modality for autoimmune arthritis. In this study, we evaluated the therapeutic effect of CP-690550 on established arthritis using an SKG arthritis model, a pathophysiologically relevant animal model for human RA. CP-690550 treatment revealed remarkable long-term suppressive effects on SKG arthritis when administered to the well-advanced disease (clinical score 3.5∼4.0). The treatment effect lasted at least 3 more weeks after cessation of drug infusion, and suppression of disease was correlated with the reduced pro-inflammatory cytokines, including IL-17, IFN-γ, and IL-6 and increased level of immunoregulatory IL-10.
참고문헌 (35)
- Firestein, G. S., "Immunologic mechanisms in the pathogenesis of rheumatoid arthritis", J. Clin. Rheumatol, 11, pp.S39~S44 (2005)
- VanderBorght, A., "The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies", Semin. Arthritis Rheum, 31, pp.160~175 (2001)
- McInnes, I. B, "Cytokines in the pathogenesis of rheumatoid arthritis", Nat. Rev. Immunol, 7, pp.429~442 (2007)
- Firestein, G. S, "Evolving concepts of rheumatoid arthritis", Nature, 423, pp.356~361 (2003)
- Fournier, C, "Where do T cells stand in rheumatoid arthritis?", Joint Bone Spine, 72, pp.527~532 (2005)
- Brand, D. D., "Immunopathogenesis of collagen arthritis", Springer Semin. Immunopathol, 25, pp.3~18 (2003)
- Klareskog, L, "Rheumatoid arthritis and its animal models: the role of TNF-alpha and the possible absence of specific immune reactions", Curr. Opin. Immunol, 11, pp.657~662 (1999)
- Horai, R., "TNF-alpha is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist- deficient mice", J. Clin. Invest, 114, pp.1603~1611 (2004)
- Hata, H., "Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice", J. Clin. Invest, 114, pp.582~588 (2004)
- Ferrari-Lacraz, S., "Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15", Fc protein prevents disease development and progression in murine collagen-induced arthritis, 2004, pp.173, 5818~5826
- Gracie, J. A., "A proinflammatory role for IL-18 in rheumatoid arthritis", J. Clin. Invest, 104, pp.1393~1401 (1999)
- Nakae, S., "Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice", J. Immunol, 171, pp.6173~6177 (2003)
- Lubberts, E., "Treatment with a neutralizing anti- murine interleukin-17 antibody after the onset of collagen- induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion", Arthritis Rheum, 50, pp.650~659 (2004)
- Murphy, C. A., "Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation", J. Exp. Med, 198, pp.1951~1957 (2003)
- Hirota, K., "T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17＋ Th cells that cause autoimmune arthritis", J. Exp. Med, 204, pp.41~47 (2007)
- Lubberts, E., "The role of T-cell interleukin-17 in conduction destructive arthritis: lessons from animal models", Arthritis Res. Ther, 7, pp.29~37 (2005)
- Changelian, P. S., "Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor", Science, 302, pp.875~878 (2003)
- Kudlacz, E., "The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models", Am. J. Transplant, 4, pp.51~57 (2004)
- Borie, D. C., "Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in Nonhuman Primates", Transplantation, 79, pp.791~801 (2005)
- Paniagua, R., "Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in Nonhuman Primate recipients of kidney allografts", Transplantation, 80, pp.1283~1292 (2005)
- Park, H. B., "CP-690550, a Jak inhibitor, suppresses CD4＋ T cell-mediated acute graft-versus-host disease by inhibiting the IFN-g pathway", Transplantation, 90, pp.825~835 (2010)
- Ghoreschi, K., "Modulation of innate and adaptive immune responses by tofacitinib (CP- 690,550)", J. Immunol, 186, pp.4234~4243 (2011)
- Tak, P. P., "Advances in rheumatology: new targeted therapeutics", Arthritis Res. Ther, 13(Suppl 1), pp.S5~ (2011)
- Flanagan, M. E., "Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection", J. Med. Chem, 53, pp.8468~8484 (2010)
- West, K, "CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders", Curr. Opin. Investig. Drugs, 10, pp.491~504 (2009)
- Milici, A. J., "Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis", Arthritis Res. Ther, 10, pp.R14~ (2008)
- Sakaguchi, N., "Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice", Nature, 426, pp.454~460 (2003)
- Yoshitomi, H., "A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice", J. Exp. Med, 201, pp.949~960 (2005)
- Sakaguchi, S., "Spontaneous development of autoimmune arthritis due to genetic anomaly of T cell signal transduction: Part 1", Semin. Immunol, 18, pp.199~206 (2006)
- Oh, K., "A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors", J. Immunol. Methods, 354, pp.45~52 (2010)
- Asadullah, K., "Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis", Curr. Drug Targets Inflamm. Allergy, 3, pp.185~192 (2004)
- You, S., "Immunoregulatory pathways controlling progression of autoimmunity in NOD mice", Ann. N. Y. Acad. Sci, 1150, pp.300~310 (2008)
- Cope, A. P., "The central role of T cells in rheumatoid arthritis", Clin. Exp. Rheumatol, 25, pp.S4~S11 (2007)
- Podojil, J. R., "Molecular mechanisms of T-cell receptor and costimulatory molecule ligation", blockade in autoimmune disease therapy, 2009, pp.229, 337~355
- Appel, S., "Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions", Endocr. Metab. Immune Disord. Drug Targets, 7, pp.93~97 (2007)